Loading stock data…
Axsome Therapeutics (AXSM)
$241.12-0.55 (-0.23%)
Market ClosedLast close Jun 29
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Axsome Therapeutics, Inc. in the Healthcare sector is trading at $241.12 with a market capitalization of $12.9B. Wall Street consensus targets $276.47 (21 analysts), implying a +14.7% move over the next 12 months. The stock is currently near its 52-week high of $260.19, remaining 40.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +14.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $191.20M↓ | $196.00M↑ | $170.99M↑ | $150.04M↑ | $121.46M |
| Gross Profit | $176.48M↓ | $183.67M↑ | $159.08M↑ | $136.59M↑ | $111.67M |
| Operating Income | -$62.77M↓ | -$36.02M↓ | -$32.92M↑ | -$44.82M↑ | -$55.47M |
| Net Income | -$64.54M↓ | -$28.56M↑ | -$47.23M↑ | -$47.97M↑ | -$59.41M |
Peer Comparison
JNJUNHPFE
Fundamentals
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextrometho...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.92B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-344.96%
Volume
Today's trading volume
1.07M
Recent News
Harmony Biosciences Stock Outlook as Wakix Growth Meets Pipeline
Harmony Biosciences is leveraging Wakix growth to expand its neuroscience pipeline, while advancing pitolisant programs and rare disease assets.
3 Under-the-Radar Stocks to Buy and Hold for a Decade
All three could become highly prominent biotech companies within 10 years.
Rapport ‘fully prepared’ to launch seizure drug solo, CEO says
In a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brain drugmakers.
Axsome Therapeutics Readies Auvelity Alzheimer’s Agitation Launch, Expands CNS Pipeline
Axsome Therapeutics (NASDAQ:AXSM) executives said the company is preparing to launch Auvelity in Alzheimer’s disease agitation this month while continuing to expand the drug’s use in major depressive disorder and advance a broad central nervous system pipeline. Speaking at a Jefferies fireside chat
Does SUNOSI Patent Peace And New Migraine Data Change The Bull Case For Axsome Therapeutics (AXSM)?
Axsome Therapeutics recently resolved all U.S. patent litigation related to its wake-promoting therapy SUNOSI, granting five companies rights to market generics starting in 2040, while also presenting new SYMBRAVO migraine data at the American Headache Society’s 68th Annual Meeting. This combination of long-dated intellectual property clarity for SUNOSI and fresh clinical evidence for SYMBRAVO reshapes how investors may view Axsome’s product durability and migraine franchise. We’ll now...